Metformine Accord (Metformin Hydrochloride)

Metformin works primarily by inhibiting hepatic glucose production, reducing the amount of glucose released into the bloodstream. It also decreases intestinal glucose absorption and enhances the sensitivity of muscle cells to insulin, allowing more efficient uptake of glucose from the blood.

The exact dose of Metformine Accord is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of metformin during pregnancy or lactation is not fully established. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women. Women should discuss their specific situation with a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformine Accord belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not stimulate insulin release, reducing the risk of hypoglycaemia. Its primary actions are on hepatic glucose output and insulin sensitivity.

Metformine Accord should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metformine Accord is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious potential risk is lactic acidosis, a rare but life‑threatening condition characterized by buildup of lactate in the blood. Signs include rapid breathing, muscle pain, abdominal discomfort, and unusual fatigue. Prompt medical attention is required if these symptoms appear.

Metformine Accord is contraindicated in individuals with severe renal impairment, acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who have experienced lactic acidosis while on metformin therapy. Patients with these conditions should discuss alternative treatments with their clinician.